ADMA Biologics Inc vs iShares MSCI France ETF — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while iShares MSCI France ETF trades at $47.54. The key difference: iShares MSCI France ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | EWQ | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $48.35 |
52-Week Low | $7.60 | $41.68 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
EWQ, the iShares MSCI France ETF, trades at $47.54, down 0.44% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF is concentrated in industrials and benefits from positive momentum in European equities, with a dividend scheduled for June 2026. Recent news highlights France's tech investments and ECB rate decisions influencing regional economic sentiment.
The outlook for EWQ is supported by favorable European market trends and institutional interest, though risks include geopolitical tensions affecting energy prices and potential ECB tightening. Investors should weigh the ETF's exposure to French equities against macroeconomic headwinds for balanced positioning.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →